Expertise in
37
conditions

Dr. Raj K. Vuppalanchi

Gastroenterology
Indiana University Health University Hospital
550 University Blvd, 
Indianapolis, IN 
Accepting New Patients
Offers Telehealth
22 Years of Experience
Expertise in
37
conditions
Indiana University Health University Hospital
550 University Blvd, 
Indianapolis, IN 

Overview

Raj Vuppalanchi is a Gastroenterologist practicing medicine in Indianapolis, Indiana. He has been practicing medicine for over 22 years.

Dr. Vuppalanchi is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis (NASH), Cirrhosis, Liver Transplant, and Gastric Bypass.

He is actively involved in clinical research, co-authoring 175 peer reviewed articles and participating in 11 clinical trials. Dr. Vuppalanchi is currently accepting new patients.

Specialties

Gastroenterology

Licenses

Internal Medicine in IN

Hospital Affiliations

Indiana University Health
Indiana University Health Ball Memorial Hospital
Iu Health West Hospital
Indiana University Health North Hospital
Indiana University Health Arnett Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Indiana University Health University Hospital
550 University Blvd, Indianapolis, IN 46202
Other Locations
IU Health Methodist Hospital
1701 Senate Blvd, Indianapolis, IN 46202

Additional Areas of Focus

Dr. Vuppalanchi has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Enrollment Status: Terminated
Publish Date: June 30, 2026
Intervention Type: Drug
Study Drug: Belapectin
Study Phase: Phase 2/Phase 3
Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis
Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis
Enrollment Status: Active_not_recruiting
Publish Date: April 17, 2026
Intervention Type: Other
Study Phase: Not Applicable
A Prospective, Randomized, Double-Blind, Sham-Controlled, Multi-Center, Pivotal Study to Evaluate the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes With Inadequate Glycemic Control
A Prospective, Randomized, Double-Blind, Sham-Controlled, Multi-Center, Pivotal Study to Evaluate the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes With Inadequate Glycemic Control
Enrollment Status: Suspended
Publish Date: November 13, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Placebo-Controlled, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency (AATD) [SEQUOIA]
A Placebo-Controlled, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency (AATD) [SEQUOIA]
Enrollment Status: Completed
Publish Date: November 04, 2025
Intervention Type: Other, Drug
Study Drug: ARO-AAT
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 2
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
Evaluation of Pharmacokinetics and Safety of Saroglitazar Magnesium in Participants with Normal Hepatic Function and with Hepatic Impairment, Cholestatic Liver Disease, NASH with Advanced Fibrosis
Evaluation of Pharmacokinetics and Safety of Saroglitazar Magnesium in Participants with Normal Hepatic Function and with Hepatic Impairment, Cholestatic Liver Disease, NASH with Advanced Fibrosis
Enrollment Status: Completed
Publish Date: September 20, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS )
A Phase 2, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS )
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
Enrollment Status: Terminated
Publish Date: March 09, 2023
Intervention Type: Drug
Study Drug: Obeticholic Acid 
Study Phase: Phase 4
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
Enrollment Status: Completed
Publish Date: September 16, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

175 Total Publications

A reasonably likely surrogate endpoint for metabolic dysfunction-associated steatohepatitis.
A reasonably likely surrogate endpoint for metabolic dysfunction-associated steatohepatitis.
Journal: Nature medicine
Published: April 28, 2026
Similar Doctors
Expertise in
28
conditions
Dr. Evan L. Fogel
Gastroenterology
Expertise in
28
conditions
Dr. Evan L. Fogel
Gastroenterology
Referral may be required

Indiana University Health University Hospital

550 University Blvd, 
Indianapolis, IN 
 (0.1 miles away)
317-278-6997
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Evan Fogel is a Gastroenterologist practicing medicine in Indianapolis, Indiana. Dr. Fogel is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Hereditary Pancreatitis, Chronic Pancreatitis, Sphincter of Oddi Dysfunction, Endoscopy, and Lithotripsy. Dr. Fogel is currently accepting new patients.

Expertise in
26
conditions
Dr. Naga P. Chalasani
Gastroenterology
Expertise in
26
conditions
Dr. Naga P. Chalasani
Gastroenterology
Referral may be required

Office

550 University Blvd Ste 1710, 
Indianapolis, IN 
 (0.9 miles away)
317-944-0980
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Naga Chalasani is a Gastroenterologist practicing medicine in Indianapolis, Indiana. Dr. Chalasani is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis (NASH), Cirrhosis, Liver Transplant, and Gastric Bypass. Dr. Chalasani is currently accepting new patients.

Expertise in
28
conditions
Dr. Marwan S. Ghabril
Gastroenterology
Expertise in
28
conditions
Dr. Marwan S. Ghabril
Gastroenterology
Referral may be required

Indiana University Health University Hospital

550 University Blvd, 
Indianapolis, IN 
 (0.1 miles away)
317-944-8660
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Marwan Ghabril is a Gastroenterologist practicing medicine in Indianapolis, Indiana. Dr. Ghabril is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Liver Failure, Ascites, Cirrhosis, Liver Transplant, and Endoscopy. Dr. Ghabril is currently accepting new patients.

Frequently Asked Questions about Dr. Raj K. Vuppalanchi

How do I make an appointment with Dr. Raj K. Vuppalanchi?

You can book an appointment with Dr. Raj K. Vuppalanchi by calling their office at 317-944-0980. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Raj K. Vuppalanchi a top-rated expert for Non-Alcoholic Fatty Liver Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Raj K. Vuppalanchi is classified as an Elite expert for Non-Alcoholic Fatty Liver Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Raj K. Vuppalanchi specialize in?

While Dr. Raj K. Vuppalanchi is a Gastroenterology, they have specific expertise in Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis (NASH), and Cirrhosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Gastroenterology.

Does Dr. Raj K. Vuppalanchi participate in research or clinical trials?

Yes. Dr. Raj K. Vuppalanchi has published 175 articles and abstracts on conditions like Non-Alcoholic Fatty Liver Disease. You can view a list of Dr. Raj K. Vuppalanchi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Raj K. Vuppalanchi accept my insurance?

Dr. Raj K. Vuppalanchi accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 317-944-0980 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vuppalanchi's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 12 Distinguished Conditions
View All 17 Advanced Conditions
View All 48 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile